Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report

Mai Zhang, Hua Yang, Ling Chen, Kunli Du, Lina Zhao, Lichun WeiFrontiers in Oncology 2022 · DOI

TL;DR

This case report details a promising new treatment strategy for a specific subset of rectal cancer patients: those with dMMR/MSI-H and KRAS mutations. By combining neoadjuvant chemoradiation with immunotherapy, the patient achieved a complete pathological response in both the primary tumor and a liver metastasis, suggesting this approach could significantly improve outcomes for this challenging group.

What Problem Does This Paper Address?

Locally advanced rectal cancer (LARC) is typically treated with preoperative chemoradiation (CRT). While effective for local control, distant metastases remain a significant concern. For patients with mismatch repair-deficient (dMMR) or high microsatellite instability (MSI-H) LARC, immunotherapy has shown promise, particularly in downstaging tumors. However, the efficacy of combining CRT with immunotherapy in patients who also have a KRAS mutation – a common mutation in colorectal cancer that can influence treatment response – is not well-established. Furthermore, the potential for such a combination to induce an "abscopal effect" (where radiation to one tumor site leads to the regression of distant, non-irradiated tumors) is an area with limited reporting. This paper addresses the need for understanding this complex treatment scenario in a patient with a dMMR/MSI-H and KRAS-mutant LARC.

Methods

The study is a case report, meaning it focuses on a single patient's experience. The treatment regimen involved:

  • Short-course radiotherapy: A brief period of radiation therapy.
  • Neoadjuvant chemotherapy: Four cycles of XELOX (capecitabine and oxaliplatin).
  • Immunotherapy: Concurrently administered with chemotherapy, using the PD-1 inhibitor tislelizumab.
  • Surgery: Total mesorectal excision (TME) was performed after the neoadjuvant treatment.
  • Diagnostic Tools: Magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and immunohistochemistry were used for diagnosis, staging, and response assessment. Next-generation sequencing (NGS) was employed for comprehensive genetic mutation analysis.

Datasets

Not discussed in the paper. This is a case report focusing on a single patient's treatment and outcome.

Key Insights and Ideas

  • Synergistic Efficacy: The combination of CRT and PD-1 inhibitor immunotherapy demonstrated remarkable clinical response, not only in the primary rectal tumor but also in a newly identified liver metastasis.
  • Potential for Abscopal Effect: The regression of the liver metastasis, which was not directly irradiated, suggests a possible abscopal effect, a phenomenon where local treatment triggers a systemic anti-tumor immune response.
  • KRAS Mutation Complexity: The case highlights that even with a KRAS mutation, which can sometimes be associated with poorer responses to certain therapies, a dMMR/MSI-H status might still allow for significant benefit from immunotherapy-based combinations.
  • Pseudoprogression as a Positive Sign: The initial appearance of a liver lesion, initially suspected as metastasis, was later deemed likely immunotherapy-related pseudoprogression, which can paradoxically be associated with better long-term outcomes.

Key Results

The patient achieved a pathological complete response (pCR) in the primary rectal tumor after the neoadjuvant treatment and surgery. Notably, a liver lesion that appeared during treatment, initially concerning for metastasis, resolved without evidence of tumor cells upon biopsy and was treated with radiofrequency ablation. The patient tolerated the combined treatment well, with only grade 2 thyroid-stimulating hormone increase as a significant toxicity. At 11 months of follow-up, there was no evidence of disease recurrence.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single Case: The findings are based on a single patient, limiting generalizability.
  • Short Follow-up: The 11-month follow-up period is relatively short for assessing long-term outcomes.
  • Liver Biopsy Limitations: The liver biopsy may not have fully represented the entire metastatic lesion.

Future work should focus on:

  • Optimizing Treatment Combinations: Further research is needed to determine the optimal way to combine CRT and immunotherapy to maximize synergistic effects while minimizing toxicity, especially for patients with complex genetic profiles.
  • Investigating Abscopal Effect: More studies are required to understand the mechanisms and prevalence of abscopal effects in this context.
  • Long-term Survival: Longer follow-up studies are crucial to confirm the sustainability of the observed responses and their impact on long-term survival.
  • Clinical Assessment of cCR: Developing consensus criteria for clinical complete response (cCR) and refining watch-and-wait strategies for LARC patients who achieve cCR after neoadjuvant therapy is important.

Summary updated

Abstract

To date, preoperative chemoradiation (CRT) is the standard of care for patients with locally advanced rectal cancer (LARC) regardless of status of mismatch repair. Immunotherapy showed promising results in the neoadjuvant treatment trials in patients with mismatch repair-deficient (dMMR) or high microsatellite instability (MSI-H) LARC. The efficacy of CRT plus programmed death 1 (PD-1) inhibitor in these patients with complex gene mutation remains unclear. Additionally, very few studies reported on whether such combination could induce abscopal effect. We report a case of dMMR and MSI-H LARC with KRAS mutation that achieved pathological complete response of primary lesion and liver metastases after neoadjuvant short-course radiotherapy followed by four cycles chemotherapy of XELOX plus PD-1 inhibitor tislelizumab and a subsequent total mesorectal excision. This case indicates that this combined treatment strategy has remarkable clinical response both in locoregional and distant diseases, which potentially leads to reduction in the risk of distant metastases and better locoregional control for this subgroup of population.
BibTeX
@inproceedings{zhang2022pathological,
  author = {Mai Zhang and Hua Yang and Ling Chen and Kunli Du and Lina Zhao and Lichun Wei},
  title = {{Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.926480},
}
Figure